Experimental Drug Development Centre (EDDC)

Investigations into an under-explored region of SARS-CoV-2’s spike protein reveals detailed structural insights that can represent valuable drug targets.

By tapping into the strengths of the innate immune system, Samantha Wong aims to develop safer, more potent cancer treatments.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

A*STAR scientists lay the foundations for a circular economy using worms that turn plastics into fertiliser.

A new smartphone app improves the reliability of on-site rapid COVID-19 colorimetric tests, paving the way for safe gatherings in the post-pandemic world.

From the public sector to innovative startups and industry giants, A*STAR scholars are blazing the trail across Singapore’s research ecosystem.

From music streaming technology to COVID-19 tests, A*STAR Assistant Chief Executive (Enterprise) Sze Wee Tan details how the agency is bringing their innovations out of the lab and into the real world.

Through the years, A*STAR has always stood at the forefront of science and technology and innovation. Here’s how A*STAR came to be and what it has in store in the upcoming decades.

A*STAR’s steady investments in R&D and talent create the ideal conditions for impactful science, says its Chief Executive Officer Frederick Chew.

Contrary to popular belief, a new A*STAR study shows that HIV mutations are far from random, emerging at specific locations at specific rates.

The discovery of a new, highly conserved druggable site on the HIV reverse transcriptase could turn the tide in the wake of growing drug resistance.

A*STAR scientists aim to design better immunotherapies by simulating the binding of antibodies to their targets.